{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:04:37Z","timestamp":1772456677011,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Liuzhou City Science and technology research projects","award":["2015J030512"],"award-info":[{"award-number":["2015J030512"]}]},{"name":"Department of Health of Guangxi Zhuang Autonomous Region Self-raised Funds Project","award":["Z20170895"],"award-info":[{"award-number":["Z20170895"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Nimotuzumab (NTZ) is an anti-EGFR monoclonal antibody. However,the effect of targeted drugs combined with induction therapy in locally advanced nasopharyngeal carcinoma remains unclear. The aim of this study is to investigate the safety and efficacy of NTZ combined with cisplatin plus 5-fluorouracil (PF) as induction regimen in locally advanced nasopharyngeal carcinoma (NPC) patients receiving concurrent radiochemotherapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a multicenter randomized controlled study performed in eight Guangxi hospitals in 2015\u20132017. Eligible patients with NPC were randomized into nimotuzumab\/PF (NPF group) and docetaxel\/PF (DPF group) regimens, respectively, as induction therapy. After 2 cycles of induction therapy, all patients received cisplatin and concurrent intensity modulated radiation therapy (IMRT). Then, the two groups were compared for safety and efficacy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 118 patients with stage III-IVa NPC were assessed, with 58 and 60 in the NPF and DPF groups, respectively. Compared with DPF treatment, NPF induction therapy showed a more pronounced effect on cervical lymph nodes (<jats:italic>P<\/jats:italic>\u2009=\u20090.036), with higher response rate (RR) (81% vs 60%). Compared with the DPF group, the NPF group showed significantly reduced leukopenia, neutropenia and gastrointestinal reactions (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05); rash only appeared in the NPF group, but all cases were grade 1. During concurrent treatment with radiotherapy and chemotherapy, the NPF group showed better tolerance to radiotherapy and chemotherapy; neutropenia, anemia, gastrointestinal reactions, oral mucositis and radiation dermatitis in the NPF group were significantly reduced (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The expression rate of EGFR was 94.9% (112\/118). Compared with the DPF group, patients with EGFR expression in the NPF group showed better response (77.8% vs 63.0%, <jats:italic>P<\/jats:italic>\u2009=\u20090.033).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>For locally advanced NPC patients receiving follow-up cisplatin and IMRT, nimotuzumab\/PF for induction therapy has better lymph node response rate and milder adverse reactions than the DPF regimen. In addition, the patients have better tolerance in subsequent concurrent radiotherapy and chemotherapy; however, long-term efficacy needs further follow-up evaluation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The registration number of the clinical trial is <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=13780\">ChiCTR-OIC-16008201<\/jats:ext-link> and retrospectively registered on March 31, 2016.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-019-6459-6","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T18:02:22Z","timestamp":1577728942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study"],"prefix":"10.1186","volume":"19","author":[{"given":"Ying","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianquan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanxiong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rensheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejian","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"6459_CR1","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.7150\/jca.20351","volume":"8","author":"SB Liang","year":"2017","unstructured":"Liang SB, Wang Y, Hu XF, He SS, Yang XL, Liu LZ, et al. Survival and toxicities of IMRT based on the RTOG protocols in patients with nasopharyngeal carcinoma from the endemic regions of China. J Cancer. 2017;8:3718\u201324.","journal-title":"J Cancer"},{"key":"6459_CR2","doi-asserted-by":"publisher","first-page":"3725837","DOI":"10.1155\/2018\/3725837","volume":"2018","author":"T Bhattacharyya","year":"2018","unstructured":"Bhattacharyya T, Babu G, Kainickal CT. Current role of chemotherapy in nonmetastatic nasopharyngeal Cancer. J Oncol. 2018;2018:3725837.","journal-title":"J Oncol"},{"key":"6459_CR3","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.3892\/ol.2017.6564","volume":"14","author":"H Yan","year":"2017","unstructured":"Yan H, Cao X, Wang J. Application of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Oncol Lett. 2017;14:7773\u20136.","journal-title":"Oncol Lett"},{"key":"6459_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.7150\/jca.16732","volume":"8","author":"H Peng","year":"2017","unstructured":"Peng H, Chen L, Zhang J, Li WF, Mao YP, Zhang Y, et al. Induction chemotherapy improved Long-term outcomes of patients with Locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy. J Cancer. 2017;8:371\u20137.","journal-title":"J Cancer"},{"key":"6459_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35:498\u2013505.","journal-title":"J Clin Oncol"},{"key":"6459_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","volume":"24","author":"YP Chen","year":"2018","unstructured":"Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, et al. Induction chemotherapy plus concurrent Chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018;24:1824\u201333.","journal-title":"Clin Cancer Res"},{"key":"6459_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2217\/fon.14.44","volume":"10","author":"J Lang","year":"2014","unstructured":"Lang J, Gao L, Guo Y, Zhao C, Zhang C, Society of H, et al. Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. Future Oncol. 2014;10:1635\u201348.","journal-title":"Future Oncol"},{"key":"6459_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/hed.24580","volume":"39","author":"SL Skulsky","year":"2017","unstructured":"Skulsky SL, O'Sullivan B, McArdle O, Leader M, Roche M, Conlon PJ, et al. Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American joint committee on Cancer and NCCN clinical practice guidelines in oncology. Head Neck. 2017;39:578\u201394.","journal-title":"Head Neck"},{"key":"6459_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.4143\/crt.2015.359","volume":"48","author":"R Kim","year":"2016","unstructured":"Kim R, Hahn S, Shin J, Ock CY, Kim M, Keam B, et al. The effect of induction chemotherapy using Docetaxel, Cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis. Cancer Res Treat. 2016;48:907\u201316.","journal-title":"Cancer Res Treat"},{"key":"6459_CR10","doi-asserted-by":"publisher","first-page":"15581","DOI":"10.1038\/s41598-018-33614-5","volume":"8","author":"Z Zeng","year":"2018","unstructured":"Zeng Z, Yan RN, Tu L, Wang YY, Chen PR, Luo F, et al. Assessment of concurrent Chemoradiotherapy plus induction chemotherapy in advanced nasopharyngeal carcinoma: Cisplatin, fluorouracil, and Docetaxel versus gemcitabine and Cisplatin. Sci Rep. 2018;8:15581.","journal-title":"Sci Rep"},{"key":"6459_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509\u201320.","journal-title":"Lancet Oncol"},{"key":"6459_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/jjco\/hyx057","volume":"47","author":"M Kawahira","year":"2017","unstructured":"Kawahira M, Yokota T, Hamauchi S, Onozawa Y, Ogawa H, Onoe T, et al. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal stage N2-3. Jpn J Clin Oncol. 2017;47:705\u201312.","journal-title":"Jpn J Clin Oncol"},{"key":"6459_CR13","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.30566","volume":"123","author":"L Kong","year":"2017","unstructured":"Kong L, Zhang Y, Hu C, Guo Y, Lu JJ. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA\/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: final results of 2 parallel phase 2 clinical trials. Cancer. 2017;123:2258\u201367.","journal-title":"Cancer"},{"key":"6459_CR14","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/cncr.10372","volume":"94","author":"RS Herbst","year":"2002","unstructured":"Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593\u2013611.","journal-title":"Cancer"},{"key":"6459_CR15","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/hed.23355","volume":"36","author":"W Sun","year":"2014","unstructured":"Sun W, Long G, Wang J, Mei Q, Liu D, Hu G. Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis. Head Neck. 2014;36:1508\u201316.","journal-title":"Head Neck"},{"key":"6459_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/CBM-140401","volume":"14","author":"X Ma","year":"2014","unstructured":"Ma X, Huang J, Wu X, Li X, Zhang J, Xue L, et al. Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: a meta-analysis. Cancer Biomark. 2014;14:267\u201377.","journal-title":"Cancer Biomark"},{"key":"6459_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hed.10307","volume":"25","author":"BB Ma","year":"2003","unstructured":"Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck. 2003;25:864\u201372.","journal-title":"Head Neck"},{"key":"6459_CR18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/cas.13589","volume":"109","author":"H Peng","year":"2018","unstructured":"Peng H, Tang LL, Liu X, Chen L, Li WF, Mao YP, et al. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Cancer Sci. 2018;109:1609\u201316.","journal-title":"Cancer Sci"},{"key":"6459_CR19","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1111\/ajco.12166","volume":"12","author":"Y Wang","year":"2016","unstructured":"Wang Y, Pan L, Sheng XF, Chen S, Dai JZ. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: first results in Chinese patients. Asia Pac J Clin Oncol. 2016;12:e23\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"key":"6459_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12885-015-1191-3","volume":"15","author":"DQ Chong","year":"2015","unstructured":"Chong DQ, Toh XY, Ho IA, Sia KC, Newman JP, Yulyana Y, et al. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer. 2015;15:255.","journal-title":"BMC Cancer"},{"key":"6459_CR21","doi-asserted-by":"crossref","first-page":"75544","DOI":"10.18632\/oncotarget.17357","volume":"8","author":"F Wang","year":"2017","unstructured":"Wang F, Jiang C, Ye Z, Sun Q, Liu T, Xu M, et al. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oncotarget. 2017;8:75544\u201356.","journal-title":"Oncotarget"},{"key":"6459_CR22","doi-asserted-by":"crossref","first-page":"24429","DOI":"10.18632\/oncotarget.8225","volume":"7","author":"ZG Liu","year":"2016","unstructured":"Liu ZG, Zhao Y, Tang J, Zhou YJ, Yang WJ, Qiu YF, et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget. 2016;7:24429\u201335.","journal-title":"Oncotarget"},{"key":"6459_CR23","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.2147\/OTT.S151554","volume":"10","author":"J Huang","year":"2017","unstructured":"Huang J, Zou Q, Qian D, Zhou L, Yang B, Chu J, et al. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma. Onco Targets Ther. 2017;10:5835\u201341.","journal-title":"Onco Targets Ther"},{"key":"6459_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2003.10.038","volume":"59","author":"DT Chua","year":"2004","unstructured":"Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:11\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6459_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.oraloncology.2016.10.011","volume":"62","author":"D Ou","year":"2016","unstructured":"Ou D, Blanchard P, El KC, De FF, Even C, Levy A, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncol. 2016;62:114\u201321.","journal-title":"Oral Oncol"},{"key":"6459_CR26","first-page":"3255","volume":"8","author":"R Tian","year":"2015","unstructured":"Tian R, Ye HX, Zhang BG, Gu DY, Zhang BW, Teng ZP, et al. Use of taxane-containing induction chemotherapy in combination with concurrent chemoradiotherapy in Chinese patients with locally advanced nasopharyngeal carcinoma: a meta-analysis. Onco Targets Ther. 2015;8:3255\u201363.","journal-title":"Onco Targets Ther"},{"key":"6459_CR27","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.7150\/jca.27611","volume":"9","author":"L Peng","year":"2018","unstructured":"Peng L, Liu ZL, Xu C, Tang LL, Liu X, Lin AH, et al. The efficacy and safety of anti-epidermal growth factor receptor monoclonal antibodies in nasopharyngeal carcinoma: literature-based meta-analyses. J Cancer. 2018;9:4510\u201320.","journal-title":"J Cancer"},{"key":"6459_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12885-018-4268-y","volume":"18","author":"H Peng","year":"2018","unstructured":"Peng H, Tang LL, Liu X, Chen L, Li WF, Mao YP, et al. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. BMC Cancer. 2018;18:323.","journal-title":"BMC Cancer"},{"key":"6459_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2018.03.002","volume":"80","author":"M Lin","year":"2018","unstructured":"Lin M, You R, Liu YP, Zhang YN, Zhang HJ, Zou X, et al. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. Oral Oncol. 2018;80:1\u20138.","journal-title":"Oral Oncol"},{"key":"6459_CR30","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.7150\/thno.19710","volume":"7","author":"R You","year":"2017","unstructured":"You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, et al. Concurrent Chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and Long follow-up. Theranostics. 2017;7:2314\u201324.","journal-title":"Theranostics"},{"key":"6459_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and Cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381:1124\u201335.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6459-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:22:38Z","timestamp":1609201358000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6459"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6459-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"23 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the Ethics Committee of the Fourth Affiliated Hospital of Guangxi Medical University (PJK2015201). Written informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1262"}}